Overview
Epignathus is an extremely rare congenital teratoma that arises from the oral cavity, most commonly from the hard or soft palate, but occasionally from the pharynx, jaw, or tongue. It is a type of oropharyngeal teratoma composed of tissues derived from all three embryonic germ layers (ectoderm, mesoderm, and endoderm), and may contain differentiated structures such as teeth, bone, cartilage, neural tissue, and skin. Epignathus is typically detected prenatally via ultrasound or at birth, presenting as a mass protruding from the mouth. The tumor is classified under ICD-10 as D37.0, reflecting its uncertain neoplastic behavior. The primary clinical concern with epignathus is airway obstruction, which can be life-threatening at birth. Large tumors may cause feeding difficulties, respiratory distress, and in severe cases neonatal asphyxia if not promptly managed. Prenatal complications may include polyhydramnios (excess amniotic fluid) due to impaired fetal swallowing, and very large masses can cause difficulty during delivery. Some cases are associated with cleft palate or other craniofacial anomalies. Rarely, intracranial extension of the tumor has been reported, which significantly complicates management. Treatment is primarily surgical excision of the mass, ideally performed as soon as the airway is secured. In cases diagnosed prenatally where significant airway compromise is anticipated, an EXIT (Ex Utero Intrapartum Treatment) procedure may be planned to establish the airway during delivery while the infant remains on placental circulation. The majority of epignathus tumors are histologically benign (mature teratomas), and complete surgical resection generally carries a favorable prognosis. However, outcomes depend on tumor size, location, degree of airway obstruction, and the presence of intracranial extension. Malignant transformation is exceedingly rare but has been reported. Long-term follow-up is recommended to monitor for recurrence and to address any residual craniofacial defects.
Also known as:
Sporadic
Usually appears on its own, not inherited from a parent
Neonatal
Begins at or shortly after birth (first 4 weeks)
Treatments
No FDA-approved treatments are currently listed for Epignathus.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Epignathus at this time.
New trials open frequently. Follow this disease to get notified.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Epignathus.
Community
No community posts yet. Be the first to share your experience with Epignathus.
Start the conversation →Latest news about Epignathus
No recent news articles for Epignathus.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Epignathus
What is Epignathus?
Epignathus is an extremely rare congenital teratoma that arises from the oral cavity, most commonly from the hard or soft palate, but occasionally from the pharynx, jaw, or tongue. It is a type of oropharyngeal teratoma composed of tissues derived from all three embryonic germ layers (ectoderm, mesoderm, and endoderm), and may contain differentiated structures such as teeth, bone, cartilage, neural tissue, and skin. Epignathus is typically detected prenatally via ultrasound or at birth, presenting as a mass protruding from the mouth. The tumor is classified under ICD-10 as D37.0, reflecting it
How is Epignathus inherited?
Epignathus follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Epignathus typically begin?
Typical onset of Epignathus is neonatal. Age of onset can vary across affected individuals.
Which specialists treat Epignathus?
15 specialists and care centers treating Epignathus are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.